Zobrazeno 1 - 3
of 3
pro vyhledávání: '"OC Lindgjærde"'
Autor:
MH Haugen, OC Lindgjærde, M Krohn, W Zhao, EM Lindholm, L Silwal-Pandit, E Borgen, Ø Garred, A Fangberget, MM Holmen, E Schlichting, H Skjerven, S Lundgren, E Wist, B Naume, GM Mælandsmo, Y Lu, A-L Børresen-Dale, GB Mills, O Engebråten
Publikováno v:
Cancer Research. 77:P6-13
BACKGROUND: Patients with HER2 negative primary tumors of ≥25 mm were treated with neoadjuvant chemotherapy (4 x FEC100 + 12 weeks of taxane-based therapy) and randomized (1:1) to receive bevacizumab or not. Mammography, ultrasound and MR imaging w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::973c3419775ceceb3c0fe346f11746c7
https://doi.org/10.1158/1538-7445.sabcs16-p6-13-01
https://doi.org/10.1158/1538-7445.sabcs16-p6-13-01
Autor:
Ellen Schlichting, Bjørn Naume, TG Lien, Elin Borgen, Anne Lise Børresen-Dale, OC Lindgjærde, HvdL Gythfeldt, Øystein Garred, Olav Engebråten, Laxmi Silwal-Pandit, Erik Wist
Publikováno v:
Cancer Research. 79:P6-07
Background: Bevacizumab added to conventional neoadjuvant chemotherapy increase the proportion of patients achieving a pathological complete response (pCR). Identifying patients responding to antiangiogenic therapy have been challenging. The primary
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::08dbe04407cc2ebd6086107014628f51
https://doi.org/10.1158/1538-7445.sabcs18-p6-07-01
https://doi.org/10.1158/1538-7445.sabcs18-p6-07-01
Autor:
Diep CB; Department of Genetics, Institute for Cancer Research, The Norwegian Radium Hospital, Norway., Kleivi K, Ribeiro FR, Teixeira MR, Lindgjaerde OC, Lothe RA
Publikováno v:
Genes, chromosomes & cancer [Genes Chromosomes Cancer] 2006 Jan; Vol. 45 (1), pp. 31-41.